Actelion
Clinical trials sponsored by Actelion, explained in plain language.
-
Higher dose tested to help people with rare lung disease live longer, stay out of hospital
Disease control OngoingThis study is testing if a higher dose (75 mg) of the drug macitentan is better than the standard dose (10 mg) at delaying serious health problems or death in adults with pulmonary arterial hypertension (PAH), a rare and serious lung disease. About 935 participants will be random…
Phase: PHASE3 • Sponsor: Actelion • Aim: Disease control
Last updated Apr 02, 2026 05:57 UTC
-
New hope for kids with rare lung disease
Disease control OngoingThis study aims to find the right dose of the medication selexipag for children with pulmonary arterial hypertension (PAH), a serious lung and heart condition. It will test the drug's safety and how it moves through the body in about 60 children aged 2 to 18. The goal is to contr…
Phase: PHASE2 • Sponsor: Actelion • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New hope for kids with rare, deadly lung disease
Disease control OngoingThis study is testing whether adding a drug called selexipag to standard treatments can slow down the worsening of pulmonary arterial hypertension (PAH) in children aged 2 to 18. PAH is a rare, serious disease that causes high blood pressure in the lungs. The trial will compare s…
Phase: PHASE3 • Sponsor: Actelion • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC